



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

8 December 2022
EMA/CVMP/QWP/907965/2022
Committee for Veterinary Medicinal Products (CVMP)

Guideline on control of impurities of pharmacopoeial substances: compliance with the European Pharmacopoeia general monograph “substances for pharmaceutical use” and general chapter “control of impurities in substances for pharmaceutical use”

Agreed by the Quality Working Party	October 2003
Adoption by CPMP	As Guideline (CPMP/QWP/6203/03) December 2003
Adoption by CVMP	17 March 2004
Presentation to the VMRFG	18 March 2004
Date for coming into operation	Immediately
Revision 1*	
Agreed by QWP	23 November 2022
Adopted by CVMP	8 December 2022
Date for coming into effect	17 February 2023

*The current revision consists of administrative changes made in order to align the guideline with Regulation (EU) 2019/6, as amended, and to align with the current EMA template for Guidance. The references to the legislation applicable and other scientific guidelines have also been updated as appropriate. As no changes were made to the scientific content, no concept paper and no public consultation were deemed necessary. The document reference number is changed to ensure correct document management. The former document reference number is EMEA/CVMP/059/04-FINAL. Note: This guideline has been prepared to facilitate the application of other guidelines and European Pharmacopoeia. No consultation is necessary.



Keywords	<i>Control, impurities, pharmacopoeial substances</i>
-----------------	--

Guideline on control of impurities of pharmacopoeial substances: compliance with the European Pharmacopoeia general monograph “substances for pharmaceutical use” and general chapter “control of impurities in substances for pharmaceutical use”

Table of contents

1. Introduction (background).....	4
2. Problem statement.....	4
3. Background information and position from the QWP.....	4
4. Compliance with European Pharmacopoeia	5
References	5

1. Introduction (background)

The European Pharmacopoeia published in its 4th Edition a general monograph "Substances for Pharmaceutical Use" (1) which has been effective since 1 January 2002. This general monograph is intended to be read in conjunction with individual monographs on substances in the Pharmacopoeia, and it covers any organic or inorganic substances that are used as active substances or excipients for the production of medicinal products for human or veterinary use. The monograph "Substances for Pharmaceutical Use" covers areas such as production, characters, identification, tests (polymorphism, related substances, residual solvents, sterility, bacterial endotoxins, pyrogens, additional properties), assay and labelling.

A revised version of the monograph was adopted at the November 2003 meeting of the European Pharmacopoeia Commission. This monograph sets the frame to prepare the specific active substances monographs.

In addition a general chapter "Control of impurities in substances for pharmaceutical use" (2), which has been adopted in November 2003 by the European Pharmacopoeia Commission, indicates the rules, how the tests on impurities (mainly the related substances test) have to be dealt with in a monograph with regard to thresholds, acceptance criteria and the transparency list (specified and other detectable impurities). It also gives an explanation how the limit for impurities in a specific monograph should be interpreted. Basically the ICH Q3A(R) concepts and thresholds for reporting, identification and qualification of impurities have been adopted. Similar concepts apply under VICH GL10.

2. Problem statement

The general monograph (1) and the general chapter (2) are mandatory in effect and therefore all substances described in specific monographs must also comply with these general requirements.

While recently adopted monographs comply to a great extent to these requirements, there are some so called "old monographs" which do not comply either not having a list of impurities (transparency statement) or having still a "related substances test" not complying with the state of the art (e.g. TLC where impurities cannot be quantified, a general limit test $\leq 0.5\%$ for single impurities, no acceptance criterion for total impurities) and therefore not complying to (1) and/or (2).

A solution was required on how to deal with the situation when faced with an application for a Marketing Authorisation (MA) using a so called "old" monograph, either through the submission of a European Pharmacopoeia Certificate of suitability (CEP), a European Active Substance Master File (ASMF) or by the submission of full data in the dossier.

3. Background information and position from the QWP

It is an absolute need to have specific active substance monographs which correspond to current scientific knowledge, especially as due to globalisation we are confronted with many different sources of a given active substance. Even if a monograph cannot necessarily cover all sources, an HPLC method is more likely to detect different impurity profiles than pharmacopoeial TLC methods. This is also why the European Pharmacopoeia Commission has revised its general policy and adopted the ICH Q3A (R) concepts and thresholds.

In addition, this is also in line with Article 23 of Directive 2001/83 which states:

"After an authorization has been issued, the authorisation holder must, in respect of the methods of manufacture and control provided for in Article 4, Article 8(3)(d) and (h) take account of technical and

scientific progress and introduce any changes that may be required to enable that medicinal product to be manufactured and checked by means of generally accepted scientific methods. These changes shall be subject to the approval of the competent authority of the Member State concerned.”

(Slightly amended version of the original Directive 65/65, article 9a).

The equivalent veterinary legislation is Article 58(3) of Regulation (EU) 2019/6.

As the European Pharmacopoeia is specifically mentioned in the legislation, it can be concluded that this statement equally applies to the monographs of the European Pharmacopoeia.

Therefore there is a need to revise these “old” monographs.

4. Compliance with European Pharmacopoeia

The process of revision of old monographs should be handled in parallel by the European Directorate for the Quality of Medicines and Healthcare (EDQM) of the Council of Europe and by the licensing authorities:

EDQM/European Pharmacopoeia:

- European Pharmacopoeia to continue its current revision programme (may be it should be identified together with the authorities, which active substances have priority and/or the QWP might also like to identify active substances for which a revision of the old monograph is not considered necessary).
- Certificate of suitability (CEP):
 - A certificate should not be granted if based on an “old” monograph i.e. not complying with (1) and/or (2). The applicant needs to make a new proposal to obtain the certificate; this would then serve as the basis for the revised monograph.
 - In the case where a CEP has been granted, based on an old monograph, a revision should be initiated during renewal of the CEP.

Licensing authorities:

- Every time an application for an MA is made by a pharmaceutical manufacturer for a medicinal product containing a pharmacopoeial active substance, the licensing authority should check, when reference to a monograph is made (e.g. CEP, EDMF), that this monograph complies with (1) and (2) above. If not, the applicant should be requested to propose a revised specification in line with the requirements in (1) and (2), before an authorisation is granted.
- This would only apply to all new applications and variations (e.g. change of manufacturer of the active substance), but not to already marketed products.
- Once a new monograph is proposed by the applicant and accepted by the licensing authority, European Pharmacopoeia should be informed and a revision of the monograph should be initiated.

References

- (1) General monograph “Substances for pharmaceutical use”, Monograph Nr 2034
- (2) General chapter “Control of impurities in substances for pharmaceutical use”, (5.10.).